Table 3 The associations of ALDH1 expression levels in stromal cells and the clinical and pathologic characteristics

Age (years old):

  ≤39

16

0 (.0 %)

5 (31.3 %)

11 (68.8 %)

  40–49

41

3 (7.3 %)

10 (24.4 %)

28 (68.3 %)

  50–59

64

2 (3.1 %)

19 (29.7 %)

43 (67.2 %)

  60–69

72

6 (8.3 %)

15 (20.8 %)

51 (70.8 %)

  ≥70

39

1 (2.6 %)

6 (15.4 %)

32 (82.1 %)

  missing

16

Histological subtype:

  Serous carcinoma

163

6 (3.7 %)

36 (22.1 %)

121 (74.2 %)

  Mucinous carcinoma

18

3 (16.7 %)

6 (33.3 %)

9 (50.0 %)

  Endometrioid carcinoma

19

0 (.0 %)

7 (36.8 %)

12 (63.2 %)

  Clear cell carcinoma

11

1 (9.1 %)

1 (9.1 %)

9 (81.8 %)

  Mixed epithelial tumor

11

0 (.0 %)

4 (36.4 %)

7 (63.6 %)

  Undifferentiated tumor

5

1 (20.0 %)

1 (20.0 %)

3 (60.0 %)

  Unclassified tumor and others

21

FIGO stage:

  I

28

2 (7.1 %)

8 (28.6 %)

18 (64.3 %)

  II

18

0 (.0 %)

10 (55.6 %)

8 (44.4 %)

  III

117

6 (5.1 %)

27 (23.1 %)

84 (71.8 %)

  IV

79

5 (6.3 %)

14 (17.7 %)

60 (75.9 %)

Not staged or missing

6

Histological grade:

  Well

19

1 (5.3 %)

9 (47.4 %)

9 (47.4 %)

  Moderate

62

2 (3.2 %)

11 (17.7 %)

49 (79.0 %)

  Poor

133

7 (5.3 %)

34 (25.6 %)

92 (69.2 %)

  Not graded or missing

34